About Knopp Biosciences
The mission of Knopp Biosciences is to discover, develop, and deliver breakthrough medicines for devastating diseases and to improve global access to health care. We target diseases imposing high costs on the healthcare system, with patient populations clearly identifiable using validated biomarkers or genetic testing.
We predicate our work on the value of collaboration, the fundamentals of quality and safety, and an unwavering commitment to our patients, partners, shareholders, community, and colleagues.
Our research has led to an investigational compound in clinical development for immunological and hematological disorders, as well as discovery platforms directed to small molecule mediators of epilepsy and neuropathic pain.
Days count for people with devastating diseases. That’s why we bring unmatched energy and a new level of collaboration with practitioners, investigators, and pharmaceutical companies in bridging the distance from the laboratory to the bedside.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.